TY - JOUR
T1 - Metformin in SARS-CoV-2 infection
T2 - A hidden path – from altered inflammation to reduced mortality. A review from the literature
AU - Pedrosa, Ana Realista
AU - Martins, Diana Cruz
AU - Rizzo, Manfredi
AU - Silva-Nunes, José
PY - 2023/2
Y1 - 2023/2
N2 - SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes.
AB - SARS-CoV-2 infection has been a major threat to human health and a huge challenge to Medicine. In only two years, COVID-19 affected >350 million people, causing >5.6 million deaths. Chronic inflammatory states, such as diabetes or obesity, are known risk factors for COVID-19 poorest outcomes, with higher risk for disease severity and greater mortality. Metformin remains on the first line of the management of hyperglycemia in type 2 diabetes. Through its anti-inflammatory and immunomodulatory mechanisms, metformin appears as an opportunity to control the dysregulated cytokine storm secondary to SARS-CoV-2 infection. Recent studies point towards a potential protective role of metformin in the course of COVID-19, showing that current or previous treatment with metformin associates with better outcomes.
KW - COVID-19
KW - Diabetes
KW - Metformin
KW - Mortality
KW - SARS-CoV-2
KW - Severity
UR - http://www.scopus.com/inward/record.url?scp=85145849800&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2022.108391
DO - 10.1016/j.jdiacomp.2022.108391
M3 - Review article
C2 - 36621213
AN - SCOPUS:85145849800
SN - 1056-8727
VL - 37
JO - Journal of Diabetes and Its Complications
JF - Journal of Diabetes and Its Complications
IS - 2
M1 - 108391
ER -